Agenus: A Would-Be Rockstar Held Back By Middling Financials [Seeking Alpha]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Seeking Alpha
The company's phase 2 trial of botensilimab in colorectal cancer is fully enrolled, with a mid-year 2024 readout likely. AGEN has various strategies to raise cash, such as a sale of non-strategic assets, but raising cash by issuing more shares is still a possibility. Agenus Inc. ( NASDAQ: AGEN ) is a biotech which has in its pipeline a very special drug, botensilimab, which is capable of treating cancer patients with tumors not normally responsive to immuno-oncology agents. When I last wrote about the company in October , I rated the stock a buy, based on the strength of the clinical data seen to date with botensilimab and the company's focus on getting the drug to market. Despite what I consider positive updates, however, and the biotech market rallying since that time, AGEN is down since I wrote about it. This article takes a look at where AGEN stands now. Botensilimab/Balstilimab remains strong Phase 2 in CRC completed enrollment months ago AGEN's next-gen anti-CTLA-4 an
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingBusiness Wire
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Agenus to Provide First Quarter 2024 Financial Report and Corporate UpdateBusiness Wire
- Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
AGEN
Earnings
- 3/14/24 - Miss
AGEN
Analyst Actions
- 3/18/24 - HC Wainwright
AGEN
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/22/24 - Form 4
- AGEN's page on the SEC website